Click here to get full coverage on Cancer drugmaker Immunome eyes desmoid tumor filing after $460M raise - Stock Titan

Cancer drugmaker Immunome eyes desmoid tumor filing after $460M raise  Stock Titan

Cancer drugmaker Immunome eyes desmoid tumor filing after $460M raise - Stock Titan

Click here to get full coverage on Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus

Immunome (IMNM) Reports Wider Losses and Revenue Decline  GuruFocus

Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus

Click here to get full coverage on Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com

Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss  marketscreener.com

Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com

Click here to get full coverage on Immunome: Q4 Earnings Insights - Benzinga

Immunome: Q4 Earnings Insights  Benzinga

Immunome: Q4 Earnings Insights - Benzinga

Click here to get full coverage on TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM - MarketBeat

TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM  MarketBeat

TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM - MarketBeat

Click here to get full coverage on How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st

How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors  simplywall.st

How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st

Click here to get full coverage on Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Yahoo Finance

Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development  Yahoo Finance

Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Yahoo Finance

Click here to get full coverage on Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win - Stock Titan

Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win  Stock Titan

Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win - Stock Titan

Click here to get full coverage on Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments - GuruFocus

Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments  GuruFocus

Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments - GuruFocus

Click here to get full coverage on Immunome, Inc. (IMNM) Investor Outlook: Exploring a Promising 60% Upside in the Biotech Sector - DirectorsTalk Interviews

Immunome, Inc. (IMNM) Investor Outlook: Exploring a Promising 60% Upside in the Biotech Sector  DirectorsTalk Interviews

Immunome, Inc. (IMNM) Investor Outlook: Exploring a Promising 60% Upside in the Biotech Sector - DirectorsTalk Interviews

Click here to get full coverage on First Week of October 16th Options Trading For Immunome (IMNM) - Nasdaq

First Week of October 16th Options Trading For Immunome (IMNM)  Nasdaq

First Week of October 16th Options Trading For Immunome (IMNM) - Nasdaq

Click here to get full coverage on Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline - Stock Titan

Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline  Stock Titan

Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline - Stock Titan

Click here to get full coverage on Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - Yahoo Finance

Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback  Yahoo Finance

Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - Yahoo Finance

Click here to get full coverage on Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM - MarketBeat

Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM  MarketBeat

Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM - MarketBeat

Click here to get full coverage on Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - simplywall.st

Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback  simplywall.st

Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - simplywall.st

Click here to get full coverage on IMNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

IMNM Financials: Income Statement, Balance Sheet & Cash Flow  Stock Titan

IMNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Click here to get full coverage on Institutional investors in Immunome, Inc. (NASDAQ:IMNM) see US$269m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance

Institutional investors in Immunome, Inc. (NASDAQ:IMNM) see US$269m decrease in market cap last week, although long-term gains have benefitted them.  Yahoo Finance

Institutional investors in Immunome, Inc. (NASDAQ:IMNM) see US$269m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance

Click here to get full coverage on Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Yahoo Finance

Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?  Yahoo Finance

Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Yahoo Finance

Click here to get full coverage on Biotech Immunome to face investors at two March conferences - Stock Titan

Biotech Immunome to face investors at two March conferences  Stock Titan

Biotech Immunome to face investors at two March conferences - Stock Titan

Click here to get full coverage on Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC - MarketBeat

Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC  MarketBeat

Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC - MarketBeat

Click here to get full coverage on New Analyst Forecast: $IMNM Given $40 Price Target - Quiver Quantitative

New Analyst Forecast: $IMNM Given $40 Price Target  Quiver Quantitative

New Analyst Forecast: $IMNM Given $40 Price Target - Quiver Quantitative

Click here to get full coverage on Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy? - Yahoo Finance

Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy?  Yahoo Finance

Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy? - Yahoo Finance

Click here to get full coverage on Insider Purchase: President and CEO of $IMNM Buys 46,511 Shares - Quiver Quantitative

Insider Purchase: President and CEO of $IMNM Buys 46,511 Shares  Quiver Quantitative

Insider Purchase: President and CEO of $IMNM Buys 46,511 Shares - Quiver Quantitative

Click here to get full coverage on Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals - Yahoo Finance

Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals  Yahoo Finance

Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals - Yahoo Finance

Click here to get full coverage on Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? - Yahoo Finance

Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed?  Yahoo Finance

Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Why Is IMNM Stock Rising Today? - Stocktwits

Why Is IMNM Stock Rising Today?  Stocktwits

Why Is IMNM Stock Rising Today? - Stocktwits

Click here to get full coverage on Friday 12/19 Insider Buying Report: IMNM, S - Nasdaq

Friday 12/19 Insider Buying Report: IMNM, S  Nasdaq

Friday 12/19 Insider Buying Report: IMNM, S - Nasdaq

Click here to get full coverage on $IMNM stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

$IMNM stock is up 8% today. Here's what we see in our data.  Quiver Quantitative

$IMNM stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Immunome (NASDAQ:IMNM) Stock Rating Upgraded by HC Wainwright - MarketBeat

Immunome (NASDAQ:IMNM) Stock Rating Upgraded by HC Wainwright  MarketBeat

Immunome (NASDAQ:IMNM) Stock Rating Upgraded by HC Wainwright - MarketBeat

Click here to get full coverage on Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results - Quiver Quantitative

Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results  Quiver Quantitative

Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results - Quiver Quantitative

Click here to get full coverage on Principal Financial Group Inc. Buys 762,147 Shares of Immunome, Inc. $IMNM - MarketBeat

Principal Financial Group Inc. Buys 762,147 Shares of Immunome, Inc. $IMNM  MarketBeat

Principal Financial Group Inc. Buys 762,147 Shares of Immunome, Inc. $IMNM - MarketBeat

Click here to get full coverage on Candriam S.C.A. Buys 541,441 Shares of Immunome, Inc. $IMNM - MarketBeat

Candriam S.C.A. Buys 541,441 Shares of Immunome, Inc. $IMNM  MarketBeat

Candriam S.C.A. Buys 541,441 Shares of Immunome, Inc. $IMNM - MarketBeat

Click here to get full coverage on Trading Systems Reacting to (IMNM) Volatility - Stock Traders Daily

Trading Systems Reacting to (IMNM) Volatility  Stock Traders Daily

Trading Systems Reacting to (IMNM) Volatility - Stock Traders Daily

Click here to get full coverage on Immunome (IMNM) Shares Surge Over 30% Following Phase 3 Data - GuruFocus

Immunome (IMNM) Shares Surge Over 30% Following Phase 3 Data  GuruFocus

Immunome (IMNM) Shares Surge Over 30% Following Phase 3 Data - GuruFocus

Click here to get full coverage on Immunome Announces Pricing of Public Offering of Common Stock - Business Wire

Immunome Announces Pricing of Public Offering of Common Stock  Business Wire

Immunome Announces Pricing of Public Offering of Common Stock - Business Wire

Click here to get full coverage on $IMNM stock is up 4% today. Here's what we see in our data. - Quiver Quantitative

$IMNM stock is up 4% today. Here's what we see in our data.  Quiver Quantitative

$IMNM stock is up 4% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Here’s Why Immunome Stock (IMNM) Soared Over 20% Today - TipRanks

Here’s Why Immunome Stock (IMNM) Soared Over 20% Today  TipRanks

Here’s Why Immunome Stock (IMNM) Soared Over 20% Today - TipRanks

Click here to get full coverage on Immunome, Inc. (IMNM) - DirectorsTalk Interviews

Immunome, Inc. (IMNM)  DirectorsTalk Interviews

Immunome, Inc. (IMNM) - DirectorsTalk Interviews

Click here to get full coverage on Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com

Immunome (IMNM) CEO Siegall buys $100k in shares  Investing.com

Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com

Click here to get full coverage on Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? - Nasdaq

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?  Nasdaq

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? - Nasdaq

Click here to get full coverage on Immunome, Inc. (IMNM) Stock Analysis: A 56% Upside Potential In Biotechnology - DirectorsTalk Interviews

Immunome, Inc. (IMNM) Stock Analysis: A 56% Upside Potential In Biotechnology  DirectorsTalk Interviews

Immunome, Inc. (IMNM) Stock Analysis: A 56% Upside Potential In Biotechnology - DirectorsTalk Interviews

Click here to get full coverage on Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha

Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM)  Seeking Alpha

Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025) - TechStock²

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)  TechStock²

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025) - TechStock²

Click here to get full coverage on Immunome (NASDAQ: IMNM) grants 19,000 inducement options to three new employees - Stock Titan

Immunome (NASDAQ: IMNM) grants 19,000 inducement options to three new employees  Stock Titan

Immunome (NASDAQ: IMNM) grants 19,000 inducement options to three new employees - Stock Titan

Click here to get full coverage on Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” - Yahoo Finance

Jim Cramer on Immunome: “If You Want to Speculate on It, Fine”  Yahoo Finance

Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” - Yahoo Finance

Click here to get full coverage on Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat (IMNM) - Seeking Alpha

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat (IMNM)  Seeking Alpha

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat (IMNM) - Seeking Alpha

Click here to get full coverage on Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors  Business Wire

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire

Click here to get full coverage on H.C. Wainwright Coverage Puts Immunome Oncology Pipeline And Execution In Focus - simplywall.st

H.C. Wainwright Coverage Puts Immunome Oncology Pipeline And Execution In Focus  simplywall.st

H.C. Wainwright Coverage Puts Immunome Oncology Pipeline And Execution In Focus - simplywall.st

Click here to get full coverage on Jim Cramer on Immunome: "If you want to speculate on it, fine" - MSN

Jim Cramer on Immunome: "If you want to speculate on it, fine"  MSN

Jim Cramer on Immunome: "If you want to speculate on it, fine" - MSN

Click here to get full coverage on Immunome Announces Proposed Public Offering of Common Stock - Business Wire

Immunome Announces Proposed Public Offering of Common Stock  Business Wire

Immunome Announces Proposed Public Offering of Common Stock - Business Wire

Click here to get full coverage on Siegall buys Immunome (IMNM) shares worth $149k - Investing.com

Siegall buys Immunome (IMNM) shares worth $149k  Investing.com

Siegall buys Immunome (IMNM) shares worth $149k - Investing.com

Click here to get full coverage on Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025) - TechStock²

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)  TechStock²

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025) - TechStock²

Click here to get full coverage on Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update  Business Wire

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on Noteworthy Monday Option Activity: MO, IMNM, RSI - Nasdaq

Noteworthy Monday Option Activity: MO, IMNM, RSI  Nasdaq

Noteworthy Monday Option Activity: MO, IMNM, RSI - Nasdaq

Click here to get full coverage on IMNM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

IMNM Earning Date, Earning Analysis and Earning Prediction  Intellectia AI

IMNM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Click here to get full coverage on Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference  Business Wire

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire

Click here to get full coverage on Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors  Business Wire

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire

Click here to get full coverage on Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026  Business Wire

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire

Click here to get full coverage on Immunome Chairman Acquires 5.8% More Stock - Yahoo Finance

Immunome Chairman Acquires 5.8% More Stock  Yahoo Finance

Immunome Chairman Acquires 5.8% More Stock - Yahoo Finance

Click here to get full coverage on Wedbush Reiterates Outperform Rating for IMNM with $31 Price Tar - GuruFocus

Wedbush Reiterates Outperform Rating for IMNM with $31 Price Tar  GuruFocus

Wedbush Reiterates Outperform Rating for IMNM with $31 Price Tar - GuruFocus

Click here to get full coverage on Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more - CNBC

Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more  CNBC

Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more - CNBC

Click here to get full coverage on Insider Buying: Clay Siegall Acquires 46,511 Shares of Immunome Inc (IMNM) - GuruFocus

Insider Buying: Clay Siegall Acquires 46,511 Shares of Immunome Inc (IMNM)  GuruFocus

Insider Buying: Clay Siegall Acquires 46,511 Shares of Immunome Inc (IMNM) - GuruFocus

Click here to get full coverage on H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛

H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40  富途牛牛

H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛

Click here to get full coverage on Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - Business Wire

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference  Business Wire

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - Business Wire

Click here to get full coverage on HC Wainwright & Co. initiates coverage of Immunome (IMNM) with buy recommendation - MSN

HC Wainwright & Co. initiates coverage of Immunome (IMNM) with buy recommendation  MSN

HC Wainwright & Co. initiates coverage of Immunome (IMNM) with buy recommendation - MSN

Click here to get full coverage on The 'Knockout' Hit That Sent This Top 3% Biotech Stock Flying - Investor's Business Daily

The 'Knockout' Hit That Sent This Top 3% Biotech Stock Flying  Investor's Business Daily

IMNM

Price Chart

Key Statistics

Technicals

About IMNM

Latest News

Cancer drugmaker Immunome eyes desmoid tumor filing after $460M raise - Stock Titan

Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus

Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com

Advanced Charts

Top Gainers

Top Losers